News: Dr. Falk Pharma Australia

NEWS

News

On this page find all the latest news, events and activities that involves Dr. Falk Pharma.

Filter news

Corporate, Press release

First patient treated in phase iib study of Naronapride in patients with gastroparesis

15.02.2023

Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both…

Corporate, Press release

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

20.10.2022

Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of…

Corporate, Press release

Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment

03.01.2022

SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology
company pioneering a precision medicine…

Corporate, Press release

Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease

02.11.2021

Dr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue…

Corporate, Press release

Renexxion Ireland Ltd. & Dr. Falk Pharma GmbH announce a Licensing and Collaboration Agreement

08.10.2021

Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal…

Corporate, Press release

TGA regulatory approval for Jorveza 0.5mg orally disintegrating tablets

01.09.2021

Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza^® 0.5mg orally disintegrating budesonide tablet -…